Oxygenta Pharmaceutical Stock Screener | Share Price & Fundamental Analysis
OXYGENTAPH
Pharmaceuticals
Screen Oxygenta Pharmaceutical share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹55.46
▼
-0.54 (-0.96%)
Market Cap
₹203.44 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
-5.54
EPS (TTM)
₹-2.69
Dividend Yield
-
Debt to Equity
-
52W High
₹124.58
52W Low
₹53.55
Operating Margin
-24.00%
Profit Margin
-15.04%
Revenue (TTM)
₹113.00
EBITDA
₹-17.00
Net Income
₹-17.00
Total Assets
₹83.00
Total Equity
₹-25.00
Oxygenta Pharmaceutical Share Price History - Stock Screener Chart
Screen OXYGENTAPH historical share price movements with interactive charts. Analyze price trends and patterns.
Oxygenta Pharmaceutical Company Profile - Fundamental Screener
Screen Oxygenta Pharmaceutical company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for OXYGENTAPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE102E01018
Oxygenta Pharmaceutical Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen OXYGENTAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 |
| Current Assets | 31 | 24 | 25 | 10 | 16 | 7 | 9 | 4 | 6 | 5 |
| Fixed Assets | 40 | 29 | 28 | 20 | 16 | 11 | 12 | 12 | 12 | 13 |
| Liabilities | ||||||||||
| Total Liabilities | 83 | 63 | 54 | 31 | 34 | 19 | 21 | 17 | 19 | 20 |
| Current Liabilities | 23 | 50 | 68 | 58 | 54 | 43 | 38 | 29 | 29 | 21 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | -25 | -20 | -46 | -35 | -38 | -41 | -35 | -32 | -27 | -22 |
| Share Capital | 37 | 34 | 14 | 14 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves & Surplus | -62 | -54 | -60 | -49 | -48 | -51 | -45 | -42 | -38 | -32 |
Screen OXYGENTAPH income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113 | 111 | 40 | 31 | 61 | 52 | 14 | 21 | 14 | 9 | 12 | 6 |
| Expenses | 130 | 119 | 49 | 38 | 59 | 48 | 22 | 23 | 17 | 13 | 17 | 10 |
| EBITDA | -17 | -9 | -10 | -7 | 2 | 4 | -8 | -2 | -3 | -4 | -4 | -4 |
| Operating Profit % | -24.00% | -9.00% | -24.00% | -23.00% | 2.00% | 7.00% | -57.00% | -10.00% | -31.00% | -59.00% | -34.00% | -66.00% |
| Depreciation | 2 | 1 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 |
| Interest | 4 | 2 | 2 | 2 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| Profit Before Tax | -23 | -12 | -14 | -11 | -1 | 3 | -6 | -4 | -5 | -6 | -6 | -7 |
| Tax | 0 | -2 | -10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 |
| Net Profit | -17 | -10 | -4 | -12 | -1 | 3 | -6 | -3 | -5 | -6 | -6 | -6 |
| EPS | -2.50 | -2.69 | -1.09 | -8.15 | -0.48 | 2.87 | -5.67 | -3.19 | -4.44 | -5.69 | -5.39 | -5.99 |
Oxygenta Pharmaceutical Cash Flow Screener - Liquidity Fundamentals
Screen OXYGENTAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 3 | -13 | -2 | -2 | -2 | -3 | -8 | 1 | 1 | 1 |
| Investing Activities | -11 | -4 | -10 | -5 | -7 | -1 | -1 | 0 | -1 | -2 |
| Financing Activities | 9 | 17 | 11 | 6 | 9 | 3 | 8 | -1 | 0 | 1 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Screen OXYGENTAPH shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 51.12% | 57.92% | 57.95% | 29.73% | 33.69% | 53.28% | 51.12% | 8.99% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.07% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 43.93% | 36.65% | 36.55% | 53.31% | 50.30% | 41.81% | 43.93% | 52.89% |
| Other Holding | 4.93% | 5.41% | 5.47% | 16.94% | 15.98% | 4.89% | 4.93% | 38.05% |
| Shareholder Count | 10,030 | 10,094 | 10,179 | 10,102 | 9,975 | 10,154 | 10,111 | 8,995 |
Oxygenta Pharmaceutical Dividend Screener - Share Yield Analysis
Screen OXYGENTAPH dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Oxygenta Pharmaceutical Index Membership - Market Screener Classification
Screen OXYGENTAPH by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Oxygenta Pharmaceutical Market Events Screener - Corporate Actions
Screen OXYGENTAPH market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 41.46% | ||
| Annual General Meeting | NA | -11.86% | ||
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | 4.96% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -8.16% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.57% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -3.62% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -9.59% |
| 2024-05-09 | 2024-05-09 | Extraordinary General Meeting | NA | 8.38% |
| 2021-12-06 | 2021-12-06 | Change Of Name | NA | 0.00% |
Oxygenta Pharmaceutical Competitors Screener - Peer Comparison
Screen OXYGENTAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 424,634 | 39.93 | 54,729 | 9.71% | 10,980 | 49.55 |
| Divis Laboratories | 172,860 | 69.20 | 9,712 | 18.67% | 2,191 | 56.33 |
| Torrent Pharmaceuticals | 129,151 | 60.10 | 11,539 | 6.99% | 1,911 | 61.47 |
| Cipla | 122,205 | 22.55 | 28,410 | 7.12% | 5,291 | 49.47 |
| Dr Reddys Laboratories | 107,114 | 18.60 | 33,741 | 16.73% | 5,725 | 60.05 |
| Lupin | 97,120 | 22.34 | 22,910 | 13.74% | 3,306 | 65.28 |
| Zydus Life Science | 92,392 | 18.40 | 23,511 | 18.55% | 4,615 | 40.07 |
| Mankind Pharma | 90,241 | 50.59 | 12,744 | 20.90% | 2,007 | 45.53 |
| Aurobindo Pharma | 71,119 | 20.79 | 32,346 | 9.43% | 3,484 | 59.88 |
| Alkem Laboratories | 67,243 | 27.59 | 13,458 | 3.70% | 2,216 | 49.80 |
Oxygenta Pharmaceutical Company Announcements - News Screener
Screen OXYGENTAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2026-01-01 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | View |
| 2025-12-11 | Intimation Under Regulation 30 The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) To Stock Exchanges Regarding Approval Of The Shareholders For Reclassification Of Person(S) Forming Part Of Th | View |
| 2025-12-11 | Minutes Of The Resolutions Passed By Way Of Postal Ballot | View |
| 2025-12-11 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | View |
| 2025-12-11 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | View |
| 2025-11-12 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Intimation Of Calendar Of Events For The Postal Ballot Process Under Regulations 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015. | View |
| 2025-11-11 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-11-07 | Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025 | View |
| 2025-11-07 | Board Meeting Outcome for Outcome Of The Board Meeting Held On 07.11.2025 | View |
| 2025-11-03 | Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025. 2. Limited Review Report For The Quarter Ended September 30 2025. 3. Any Other Business With The Permission Of The Chair. | View |
| 2025-10-22 | Disclosure Under Regulation 30 Read With Para A Part A Of Schedule III Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-10-18 | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate | View |
| 2025-10-18 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-16 | Announcement Under Regulation 30 | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-19 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-19 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |